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HDLAbstract The synthesis and antihyperlipidemic activity of some novel 4-substituted-2-substitutedm-
ethyltriazino[6,1-b]quinazolin-10-ones and 2,4-disubstituted-6,7-dimethoxy quinazoline derivatives
are described. Among the series 4-chloro-2-acetoxymethyl-3H,11H-[1,2,4]triazino[6,1-b] quinazo-
line-4,10-dione 5d has shown better activity in case of % reduction in serum cholesterol level while
4-chloro-10-oxo-10H-[1,2,4]triazino[6,1-b]quinazolin-2-yl benzoate 5f in reducing% serum triglycer-
ide level than that of the standard. 4-Hydroxyquinazolin-2-yl nicotinate 6g has signiﬁcantly increased
serumHDL level. Among the series compound 6g has shown promising results over all in lipid proﬁle.
These molecules indeed have the potential to be developed as an antihyperlipaemic molecule.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Today in most of the developed and developing countries,
hyperlipidemia and thereby atherosclerosis is the leading causeof cardiac illness and deaths (Murray and Lopez, 1997; Rosa-
mond et al., 1998). In 1984 it was demonstrated for the ﬁrst
time that there exists a link between serum cholesterol levels
and risk to Coronary Heart Disease (CHD) (McGill, 1985).
A 1% drop in serum cholesterol reduces the risk for CHD
by 2%. The agents in current use are, however, insufﬁciently
active or are accompanied by unacceptable side effects. A
reduction in LDL cholesterol concentration remains the prin-
cipal desired action, although an elevation in HDL may also
be beneﬁcial (Jain et al., 2007).
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substituted at the 2-position have been looked upon with con-
siderable interest due to their isosterism with the biologically
important quinazolin-4-ones (http://www.americanheart.org/
statistics, 2001; Sauter, 1972). Earlier, synthesis and antihyper-
lipidemic activity of a series of 2-substitutedthieno[2,3-d] pyr-
imidin-4(3H)-ones have been reported. One of the
compounds, 2-chloromethyl-5,6,7,8-tertrahydrobenzo(b)thie-
no[2,3-d]pyrimidin-4(3H)-one 1 (CAS # 89587-03-3) was found
to be most active among the series (Shiroki, 1976; Dave et al.,
1980; Shishoo et al., 1990).All these encouraging results have led theseworkers to under-
take a very systematic study into the synthesis and evaluation of
various related 2-substitutedthienopyrimidin-4-ones 2 and 3 for
antihyperlipidemic activity (Shishoo et al., 1997) Therefore, it is
concluded that the 2-chloromethylpyrimidin-4(3H)-one nucleus
4 is a potential pharmacophore for antihyperlipaemic activity.
Scientiﬁc research and clinical studies have already docu-
mented particularly the value of vitamin B3 (nicotinic acid),
and other vitamins like vitamin C, vitamin B5 (pantothenic
acid), vitamin E and caronitinin in lowering of elevated choles-
terol levels and other secondary risk factors in the blood.
Vitamins and other essential nutrients lower the particular rate
of cholesterol and other repair molecules in the liver and at the
same time, contribute to the repair of the artery wall. These
facts ignited a thought to develop novel molecules which are
basically comprising of both, vitamin B3, as well as, 2-chlo-
romethylthienopyrimidin-4-one nucleus, the latter having al-
ready demonstrated signiﬁcant potential to reduce blood
cholesterol levels (Shishoo et al., 1984, 1996). On these lines,
it was decided to link the active prodrug, thus combining
two potential pharmacophores viz, 2-chloromethyl-pyrimi-
dines with nicotinic acid to get a mutual prodrug. Recently,
we have reported the synthesis and antihyperlipidemic activity
of a series of condensed 2-chloroalkyl-4-chloro/hydroxyl-5,6-
disubstitutedpyrimidines (Davidson, 2003) In continuation to
our ongoing work herein we report a series of condensed
pyrimidines and their antihyperlipidemic activity using Triton
WR 1339 model (Arya, 1985).2. Results and discussion
2.1. Synthesis
Methyl anthranilate 8 was reﬂuxed with hydrazine hydrate to
obtain anthranilic acid hydrazide 9 which on subsequent
reﬂuxing with diethyl oxalate yielded 3-amino-2-ethoxycar-
bonylquinazolin-4-one 10 (Scheme 1).
Vanillin 11 was o-methylated with dimethyl sulfate in the
presence of aqueous KOH to get the Veratraldehyde 12 which
was treated with fuming nitric acid at 0 C with constant stir-
ring to get 3,4-dimethoxy-6-nitrobenzaldehyde 13 which fur-ther oxidized in acetone with potassium permanganate to get
the 3,4-dimethoxy-6-nitrobezoic acid 14. The next step in-
volves the esteriﬁcation reaction. The dry hydrogen chloride
gas was passed in the mixture of 3,4-dimethoxy-6-nitrobenzoic
acid 14 in anhydrous methanol for 2–3 h at 0–5 C to get
methyl-3,4-dimethoxy-6-nitrobenzoate 15. Methyl 2-amino-
4,5-dimethoxybenzoate 16 was synthesized (Scheme 2) by
reducing 2-nitro-4,5-dimethoxymethylbenzoate 15 with iron
powder (activated 80# mesh) and a catalytic amount of con-
centrated hydrochloric acid in ethanol by reﬂuxing at 80 C
for 8–9 h.
The 2-chloromethyl-3H,11H-[1,2,4]triazino[6,1-b]quinazo-
line-4,10-dione 5a and 2-(chloromethyl)quinazolin-4-ol 6a
were synthesized through the dry HCl gas catalyzed one-pot
condensation of the appropriate amino esters and chloroaceto-
nitrile (Scheme 3) as described in our earlier reports (Kathira-
van et al., 2007).
2-(Chloromethyl)-6,7-dimethoxyquinazolin-4-ol 7a was
synthesized through the dry HCl gas catalyzed one-pot con-
densation of the methyl 2-amino-4,5-dimethoxybenzoate 16
and chloroacetonitrile. The 4-chloro-2-chloromethyl-3H-
[1,2,4]triazino[6,1-b]quinazolin-10-one 5b was synthesized
(Scheme 4) using phosphorus oxytrichloride (POCl3) in
N,N-dimethyl formamide at 0–5 C (Shvedov et al., 1974).
The desired mutual prodrugs namely 2-acetoxymethyl-
3H,11H-[1,2,4] triazino[6,1-b] quinazoline-4,10-dione, 5c
2-benzyloxymethyl-3H,11H-[1,2,4]triazino[6,1-b] quinazoline-
4,10-dione, 5e 2-(2-pyridinylcarboxy)methyl-3H,11H-
[1,2,4]triazino[6,1-b] quinazoline-4, 10-dione 5g from
3H,11H,-[1,2,4]triazino[6,1-b]quinazoline-4,10-dione 5a, simi-
larly 6c, 6e, 6g from 6a and 7c, 7e, 7g from 7a were pre-
pared through the nucleophilic displacement of the
chlorine atom of the 2-chloromethyl- (Otera, 2003) with so-
dium acetate, sodium benzoate and sodium nicotinate using
dimethyl sulfoxide as the solvent with stirring for 6h at
room temperature. The workup of the reaction afforded
the corresponding desired product in good yields as shown
in (Scheme 5).
Scheme 1 Synthesis of 3-amino-2-ethoxycarbonylquinazolin-4-one.
Scheme 2 Synthesis of methyl 2-amino-4,5-dimethoxybenzoate.
Scheme 3 Synthesis of 2-(Chloromethyl)quinazolin-4-ol.
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Scheme 4 Synthesis of 4-chloro-2-chloromethyl-3H-[1,2,4]triazino[6,1-b]quinazolin-10-one.
Scheme 5 Synthesis of mutual prodrugs.
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namely 4-chloro-2-acetoxymethyl-3H,11H-[1,2,4]triazino[6,1-
b]quinazoline 4,10-dione 5d, 4-chloro-2-benzyloxymethyl-
3H,11H-[1,2,4]triazino[6,1-b]quinazoline 4,10-dione 5f, 4-chl
oro-2-(2-pyridinylcarboxy)methyl-3H,11H-[1,2,4]triazino[6, 1-
b]quinazoline 4,10-dione 5h, similarly 6d, 6f, 6h and 7d, 7f, 7h
were prepared through chlorination by chlorinating agent phos-
phorusoxytrichloride (POCl3) in the presence of phosphorus
pentachloride (PCl5) from displacement products in good yields
(Scheme 6).
Table 1 summarizes all the products formed and their phys-
ical properties.
2.2. Biological activity
The lipid lowering activity of the twenty four synthesized
compounds were evaluated using Triton WR 1339 model(Chrysselis et al., 2000). Triton injection causes the accumula-
tion of triglyceride (neutral fat), cholesterol and phospholipids
produced in the plasma for about 36 h, after which time a ra-
pid diminution begins. Excess triglyceride begins both to accu-
mulate and to disappear, respectively, before the other two
substances. The lipid proﬁle (cholesterol, triglycerides, and
HDL) for the hyperlipidemic and control Wistar rats was stud-
ied with an oral administration of the test compounds (5a–5h),
(6a–6h) and (7a–7h).
It was found that the test compounds showed signiﬁcant
changes in lipid proﬁle, i.e., decrease in total cholesterol, tri-
glycerides and increase in HDL at dose of 400 mg/kg body
weigh p.o. as compared with the control group.
All the 24 compounds (5a–5h), (6a–6h) and (7a–7h) were
tested, out of which compounds (5d, 5e, 7a, 7g, 7h, 6c, 6g, 6b,
6d, 6h) were superior in reducing % serum cholesterol
level showing (67.90 ± 0.35, 51.98 ± 2.18, 52.34 ± 1.73,
Scheme 6 Chlorination of the mutual prodrugs.
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46.56 ± 1.53, 65.68 ± 0.24, and 57.07 ± 5.36%) than the
standard drug gemﬁbrozil (42.42 ± 1.2%).
The test compounds (5c, 5f, 5h, 7c, 7e, 7g, 6e, 6g, 6f) have
shown superior activity (46.23 ± 13.05, 58.32 ± 2.16,
50.37 ± 6.45, 39.82 ± 9.79, 57.09 ± 1.84, 54.96 ± 4.96,
55.19 ± 2.08, 48.27 ± 5.98, and 46.86 ± 2.61%) in terms of
% reduction in serum triglyceride levels when compared to
standard 37.57 ± 1.68. In case of % change in serum HDL le-
vel (6e, 6g, 6f) compounds showed higher % change in HDL
levels (41.48 ± 3.85, 52.73 ± 4.79, 41.24 ± 2.88%) than stan-
dard gemﬁbrozil.
The test compound with superior activity in reducing total
serum cholesterol level is 5a, however, did not show much
reduction in triglycerides as well as not much change in
HDL levels. The best compound for reducing triglycerides lev-
els among the series is 5f. The test compounds were found to
be uniquely reducing either total serum cholesterol or triglyc-
erides levels such as 5a and 5f. The test compound 6g has in-
creased HDL levels signiﬁcantly among the series. The SAR
reveals that the presence of 2-acetoxy, 4-chloro groups contrib-
ute more for reducing total serum cholesterol levels where as
2-benzoxy group may play a key role in reducing triglyceride
levels. The incorporation of nicotine moiety as mutual prodrug
approach has signiﬁcantly increased HDL levels such as in 6g.
Table 2 summarizes all the results for antihyperlipidemic
activity.3. Experimental
The melting points were determined in an open capillary on
Veego (model: VMP-D) electronic apparatus and are uncor-
rected. The IR spectra of synthesized compounds were re-
corded on Perkin Elmer spectrum BX. FT-IR
Spectrophotometer in potassium bromide discs. The 1H
NMR spectra were recorded in DMSO-d6 using NMR Var-
ian-Mercury 300 MHz spectrometer at Punjab University,
Chandigarh and chemical shifts are given in units as parts
per million, downﬁeld from tetramethylsilane (TMS) as an
internal standard. Mass spectra were obtained on an ElectronImpact mass spectrometer at 70 eV ionizing beam and using
direct insertion probe. Table 3 summarizes the spectral data
for the representative compounds from the series.
3.1. Synthesis of 3-amino-2-ethoxycarbonylquinazolin-4(H)-one
10
3.1.1. Synthesis of anthranilic acid hydrazide 9
Methyl anthranilate 8 (10 ml, 0.065 mol) and hydrazine hy-
drate (9.57 ml, 0.2 mol) were reﬂuxed for 2 h. The reaction
mixture was cooled avoiding direct exposure to sunlight. Solid
crystals of anthranilic acid hydrazide separated out were
washed with isopropyl alcohol to yield anthranilic acid hydra-
zide (9, 9.79 g, 97.4%) m.p. 118–120 C (121–123 C) (Kathir-
avan et al., 2007).
3.1.2. Synthesis of 3-amino-2-ethoxycarbonylquinazolin-4(3H)-
one 10
A mixture of anthranilic acid hydrazide (9, 9.79 g, 0.06 mol)
and diethyl oxalate (19.5 g, 0.13 mol) was reﬂuxed with stirring
in an oil bath at 180 for 6 h. The excess of diethyl oxalate was
removed in vacuo to give a semi-solid product which became
crystalline on treatment with ethanol. The product obtained
was recrystallized from dichloromethane to yield 3-amino-2-
ethoxycarbonylquinazolin-4(3H)-one (10, 9.6 g, 62.2%) m.p.
132–135 C (137–138 C) (George et al., 1971).
3.2. Synthesis of methyl-2-amino-4,5-dimethoxybenzoate 16
(Carpenter et al., 1979)
3.2.1. Synthesis of 3,4-dimethoxybenzaldehyde 12
An aqueous solution of KOH (30.3 g in 49.5 ml water) was
added dropwise into themelted vanillin 11 (50.0 g, 0.3 mol) with
constant stirring. Simultaneously dimethyl sulfate (52.8 g,
0.39 mol) was added drop wise with continuous stirring till the
additionwas complete. Themixturewas transferred to porcelain
dish andkept overnight, thenwashedwith ice coldwater (50 ml),
ﬁltered under suction and dried in vacuum desiccators. The
product obtained was recrystallized from methanol to yield
3,4-dimethoxybenzaldehyde (12, 51.0 g, 93.4%) m.p. 43–45 C
(44 C).
Table 1 Chemical structures and properties of 4-substituted-2-substitutedmethyltriazino[6,1-b]quinazolin-10-ones and 2,4-disubsti-
tuted-6,7-dimethoxyquinazoline.
Compound R1 R2 R3 X % Yield
a Melting point* Mol. formula Recrystn. solvent Reference
5a – – Cl OH 54 240–242 C11H7ClN4O2 Methanol–Chloroform –
5b – – Cl Cl 60 133–135 C11H8Cl2N4O Benzene–Methanol –
5c – – OCOCH3 OH 73 108–110 C13H10N4O4 Methanol–Chloroform –
5d – – OCOCH3 Cl 62 >300 C13H9ClN4O3 Benzene–Methanol –
5e – – OCOC6H5 OH 83.12 172–175 C18H12N4O4 Methanol–Chloroform –
5f – – OCOC6H5 Cl 53 200–202 C18H11ClN4O3 Benzene–Methanol –
5g – – OCOC5H5N OH 80 203–205 C17H11N5O4 Methanol–Chloroform –
5h – – OCOC5H5N Cl 58 140–143 C17H10ClN5O3 Methanol–Chloroform –
6a H H Cl OH 92 248–250 C9H7ClN2O Ethanol–Chloroform –
6b H H Cl Cl 64.30 108–110 C9H6Cl2N2 Benzene–Methanol –
6c H H OCOCH3 OH 82.40 210–212 C11H10N2O3 Methanol–Chloroform –
6d H H OCOCH3 Cl 43.80 148–150 C11H9ClN2O2 Benzene–Methanol –
6e H H OCOC6H5 OH 76.30 120–124 C16H12N2O3 Methanol–Chloroform –
6f H H OCOC6H5 Cl 32.30 104–106 C16H11ClN2O2 Benzene–Methanol –
6g H H OCOC5H4N OH 80.00 290–294 C15H11N3O3 Methanol–Chloroform –
6h H H OCOC5H4N Cl 39.60 132–134 C15H10ClN3O2 Benzene–Methanol –
7a OCH3 OCH3 Cl OH 84 242–245(242–244) C11H11ClN2O3 Ethanol–Chloroform Shishoo
et al. (1984)
7b OCH3 OCH3 Cl Cl 42.80 162–164 C11H10Cl2N2O2 Hexane –
7c OCH3 OCH3 OCOCH3 OH 80.16 224–226 C13H14 N2O5 Methanol–Chloroform –
7d OCH3 OCH3 OCOCH3 Cl 34.30 140–142 C13H13ClN2O4 Benzene–Methanol –
7e OCH3 OCH3 OCOC6H5 OH 64.50 256–258 C18H16N2O5 Methanol–Chloroform –
7f OCH3 OCH3 OCOC6H5 Cl 38.40 122–124 C18H15ClN2O4 Benzene–Methanol –
7g OCH3 OCH3 OCOC5H4N OH 54.60 280–282 C17H15N3O5 Methanol–Chloroform –
7h OCH3 OCH3 OCOC5H4N Cl 42.60 134–136 C17H14ClN3O4 Methanol–Chloroform –
a Isolated yields.
* Melting points are uncorrected.
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To a stirred solution of conc. HNO3 (310 ml) in an ice water
bath (0–5 C), veratraldehyde 12 (50.0 g, 0.3 mol) was added
over a period of 45 min. After the addition, the reaction mix-
ture was allowed to stand at 15 C for 30 min in dark and then
poured in ice cold water (1 l). The yellow voluminous precipi-
tated product was obtained which was then ﬁltered at suction,
washed with ice cold water, dried and recrystallized from
methanol to yield yellow crystalline product. The product ob-
tained was 3,4-dimethoxy-6-nitrobenzaldehyde (13, 40.0 g,
62.6%) m.p. 132–134 C (133 C).
3.2.3. Oxidation to 3,4-dimethoxy-6-nitrobenzoic acid 14
In a conical ﬂask it 3,4-dimethoxy-6-nitrobenzaldehyde 13
(40 g, 0.01 mol) was dissolved in acetone (25 ml) at RT. Anaq. solution of potassium permanganate (100 g in 25 ml water)
was charged drop wise over a period of 20 min. The solution
was stirred at RT for another 2 h. The reaction mass changed
from dark gray to violet at the end of the addition, then the
reaction mass was ﬁltered and washed with hot water. The ﬁl-
trate was concentrated to remove excess of acetone and acidi-
ﬁed with conc. HCl. The precipitate formed was ﬁltered,
washed with cold water and dried under vacuum to give yellow
solid. The product obtained was recrystallized from methanol
to yield 3,4-dimethoxy-6-nitrobenzoic acid (14, 25.6 g, 75%)
m.p. 191–194 C (192–194 C).
3.2.4. Esteriﬁcation to methyl-3,4-dimethoxy-6-nitrobenzoate 15
To a solution of 3,4-dimethoxy-6-nitrobenzoic acid 14 (25 g,
0.01 mol) in methanol (100 ml) dry HCl gas was bubbled over
Table 2 Triton induced antihyperlipidemic activity of 4-
substituted-2-substitutedmethyl triazino [6,1-b]quinazolin-10-
ones and 2,4-disubstituted-6,7-dimethoxyquinazoline.
Compound % Reduction in
serum levels of
total cholesterol
% Reduction in
serum levels of
triglyceride
% Change in
serum levels
of HDL
5a 32.06 ± 2.64 29.74 ± 2.98 8.02 ± 2.81
5b 36.48 ± 0.65 31.35 ± 0.65 15.10 ± 1.01
5c 11.38 ± 3.45** 46.23 ± 13.05 23.29 ± 2.60
5d 67.90 ± 0.35** 14.69 ± 1.03* 8.69 ± 1.98
5e 51.98 ± 2.18 19.93 ± 1.77 9.86 ± 1.95
5f 35.16 ± 1.90 58.32 ± 2.16 20.89 ± 2.82
5g 42.15 ± 2.46 29.80 ± 13.8 20.60 ± 4.16
5h 4.39 ± 3.39** 50.37 ± 6.45 5.18 ± 3.54
6a 22.44 ± 2.56** 19.37 ± 2.17 10.89 ± 2.01
6b 46.56 ± 1.53 36.68 ± 0.45 14.20 ± 2.80
6c 63.27 ± 0.90** 3.16 ± 0.92** 16.02 ± 3.29
6d 65.68 ± 0.24** 2.99 ± 2.12** 3.09 ± 1.29*
6e 14.03 ± 1.22** 55.19 ± 2.08 41.48 ± 3.85**
6f 15.08 ± 1.78** 46.86 ± 2.61 41.24 ± 2.88**
6g 56.35 ± 3.84** 48.27 ± 5.98 52.73 ± 4.79**
6h 57.07 ± 5.36 38.42 ± 4.57 3.16 ± 0.94*
7a 52.34 ± 1.73 21.41 ± 3.12 25.93 ± 1.91
7b 21.81 ± 2.65** 38.39 ± 3.06 29.40 ± 5.58**
7c 4.00 ± 2.69** 39.82 ± 9.79 3.50 ± 2.12
7d 30.09 ± 2.39* 38.09 ± 2.40 32.47 ± 2.79**
7e 20.12 ± 1.47** 57.09 ± 1.84 22.06 ± 3.05
7f 25.08 ± 1.92** 26.41 ± 3.58 22.73 ± 2.63
7g 45.21 ± 3.86 54.96 ± 4.96 21.69 ± 2.20
7h 62.07 ± 3.67** 42.06 ± 3.23 1.08 ± 0.39**
Gemﬁbrozil 42.42 ± 1.2 37.57 ± 1.68 15.1 ± 1.3
Each value is the mean ± SEM of ﬁve mice.
** p< 0.01.
* p< 0.05 compared with control, Statistical analysis by one way
ANOVA followed by Dunnett’s test.
Table 3 Spectral data of representative compounds from the
series.
Compound Spectral data
10 IR, ~m/cm1: 3340, 3279 (NH), 1739 (COOEt), 1685
(N–C‚O). 1H NMR (DMSO-d6), d: 1.41 (t, 3H,
COOCHCH3), 4.50 (q, 2H, COOCH2CH3), 5.30 (s,
2H, NH2), 7.3–7.7 (m, 4H, Ar-H). MS, m/z: 233 (M
+).
Anal. Calcd for C11H11N3O3: C, 56.65; H, 4.75; N,
18.02. Found: C, 56.52; H, 4.64; N, 18.00
5a IR, ~m/cm1: 2896 (C–H), 1688 (CONH), 778 (C–Cl).
1H NMR (DMSO-d6), d: 4.2 (s, 2H, CH2), 7–8 (m, 5H,
Ar-H) 12.5 (s, 1H, NH). MS, m/z: 262 (M+). Anal.
Calcd for C11H7ClN4O2: C, 50.30; H, 2.69; N, 21.33.
Found: C, 50.11; H, 2.51; N, 21.17
5b IR, ~m/cm1: 1608 (N–C‚O), 715–764 (C–Cl). 1H
NMR (DMSO-d6), d: 4.5 (s, 2H, CH2), 7–8 (m, 5H,
Ar-H & NH). MS, m/z: 282 (M+). Anal. Calcd for
C11H8Cl2N4O: C, 47.00; H, 2.15; N, 19.93. Found: C,
47.18; H, 2.31; N, 19.99
5g IR, ~m/cm1: 1726 (OCOC5H5N), 1672 (N–C‚O).
1H
NMR (DMSO-d6), d: 5.3 (s, 2H, CH2), 7.6–7.8 (m, 4H,
Ar-H). MS, m/z: 349 (M+). Anal. Calcd for
C17H11N5O4: C, 58.45; H, 3.17; N, 20.05. Found: C,
58.69; H, 3.29; N, 20.24
7c IR, ~m/cm1: 3409 (NH), 1673 (CONH), 1741
(OCOCH3), 864 (C–Cl).
1H NMR (DMSO-d6), d: 3.90
(s, 6H, OCH3), 5.23 (s, 2H, H), 7.59 (t, 1H, H), 8.81(d,
1H, H), 9.13 (s, 1H, H), 12.35 (s, 1H, NH). MS, m/z:
278 (M+). Anal. Calcd for C13H14N2O5: C, 54.55; H,
4.58; N, 10.60. Found: C, 54.75; H, 4.71; N, 10.79
7g IR, ~m/cm1: 2847 (COCH3), 673 (CONH), 1741
(OCOC5H4N), 737 (C–Cl).
1H NMR (DMSO-d6), d:
3.90 (s, 6H, OCH3), 5.23 (s, 2H, H), 7.59 (t, 1H, H),
8.81 (d, 1H, H), 9.13 (s, 1H, H), 12.53 (s, 1H, NH).
MS, m/z: 341 (M+). Anal. Calcd for C17H15 N3O5: C,
58.72; H, 4.00; N, 12.84. Found: C, 58.54; H, 4.09; N,
12.68
7h IR, ~m/cm1: 2922 (COCH3), 1722 (OCOC5H4N).
1H
NMR (DMSO-d6), d: 4.01 (s, 6H, OCH3), 4.85 (s, 2H,
H), 7.36 (s, 1H, H), 7.43 (s, 1H, H). MS, m/z: 359
(M+). Anal. Calcd for C17H14ClN3O4: C, 55.58; H,
3.50; N, 12.15. Found: C, 55.74; H, 3.81; N, 12.22
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was observed after 2–3 h. Then the solution was concentrated
to half of its original volume. The reaction mixture was ex-
tracted with chloroform, washed with aq. NaHCO3 solution
(10% w/v), dried and concentrated to give a yellow colored so-
lid. The product obtained was the yield recrystallized from
methanol to 6-nitro-3,4-dimethoxymethylbenzoate (15, 16 g,
79%) m.p. 141–142 C (142–143 C).
3.2.5. Synthesis of methyl 2-amino-4,5-dimethoxybenzoate 16
A mixture of iron (24 g, 0.62 mol), ethanol (100 ml) and conc.
HCl (9 ml.) was stirred with mechanical stirrer and reﬂuxed
for 30 min. To the above mixture 6-nitro-4,5-dimethoxymethy-
lbenzoate (16 g, 0.019 mol) was added. The reaction mixture
was allowed to reﬂux with stirring for 12 h and the progress of
reaction was monitored by TLC. The reaction mixture was
cooled to RT, neutralized with aq sodium carbonate (10% w/
v) and ﬁltered. The ﬁltrate was concentrated to 20 ml, cooled
and poured in ice–water mixture (100 ml). The solid obtained
was ﬁltered and washed with cold water followed by washing
with aq. potassium thiocyanate solution (10% w/v) to remove
iron impurities. The product obtained was methyl 2-amino-
4,5-dimethoxymethylbenzoate (16, 3.2 g, 74%) m.p. 120–
122 C (120–121 C). recrystallized from methanol.3.3. Synthesis of 2-(chloromethyl)quinazolin-4-ol – general
procedures
A stream of dry hydrogen chloride gas was bubbled into
anice-cold solution of 3-amino-2-ethoxycarbonylester
(0.0085 mol) and chloroacetonitrile (0.017 mol) in dry dioxane
(30 ml) for 6 h. The reaction mixture was poured into ice–water
mixture and neutralized with strong ammonium hydroxide
solution (10% v/v). The precipitate separated was ﬁltered,
washed with cold water and dried. The product obtained was
recrystallized from methanol–chloroform to yield 2-chloro-
methyl-compound.
3.4. Synthesis of 4-chloro-2-chloromethylquinazoline – general
procedures
2-(Chloromethyl)quinazolin-4-ol (0.0038 mol) was dissolved in
10 ml of dry DMF. To this solution POCl3 (5 ml) was added
drop wise with continuous stirring at 0–5 C for 30 min.
The progress of the reaction was monitored by TLC. On
S402 M.K. Kathiravan et al.completion the reaction mixture was poured onto ice–water
mixture to get the solid. The product obtained was recrystal-
lized from benzene methanol (Shvedov et al., 1974).
3.5. Synthesis of prodrugs of 2-(chloromethyl)quinazolin-4-ol –
general procedures
To a solution of sodium acetate or benzoate or nicotinate
(0.09 mol) in DMSO (50 ml), 2-(chloromethyl)quinazolin-4-ol
(0.023 mol) was added and the reaction mixture was allowed
to stir for 6 h at RT. The reaction mixture was thereafter
poured onto ice water mixture (150 ml) where upon solid sep-
arated out. The product obtained was recrystallized from
methanol–chloroform.
3.6. Synthesis of 4-chloro derivatives of prodrugs – general
procedures
2-Acetoxy/benzyloxy/pyridinylcarboxymethyl derivatives
(0.0069 mol) was added to POCl3 (0.017 mol) with continuous
stirring maintaining the temp at 0–5 C for 30 min. PCl5
(0.017 mol) was then added and the solution was stirred for
further 30 min at 0–5 C. The solution was reﬂuxed further
for 4–5 h. The progress of the reaction was monitored by
TLC. The reaction mixture was poured into ice water to get
crude solid which was ﬁltered, dried. The product obtained
was recrystallized from benzene–methanol.
3.7. Biological screening
3.7.1. General conditions of experimental animals
The experiments were carried out with Wistar Albino rats. The
animals were housed at a temperature of 30 ± 5 C and
humidity of 40–50% with 12 h light and 12 h dark cycles.
The animals were given food and water ad libitum, unless spec-
iﬁed otherwise.
3.7.2. Triton–induced hyperlipidemic rat model (Triton WR
1339)
3.7.2.1. General conditions of experimental animals. Albino rats
(150–200 g) of Wistar strain of either sex were used for the
study. The animals were kept at optimum temperature condi-
tion (25–30 C) and humidity of 45%± RH.
The animals were divided into four groups of six animals
each:
3.7.2.2. Control group. The control group received only vehicle
(2% acacia solution as well as normal saline).
3.7.2.3. Cholesterol-control group. The cholesterol-control
group received Triton WR 1339 (200 mg/kg) by i.p. route in
normal saline solution.
3.7.2.4. Test group. The test drug treated group received Triton
WR 1339 (200 mg/kg i.p.) as well as test drug as suspension in
2% acacia (400 mg/kg, p.o.).
3.7.2.5. Standard group. Standard group received Triton WR
1339 (200 mg/kg i.p.) as well as gemﬁbrozil (400 mg/kg, p.o.)
as suspension in 2% acacia.3.7.3. Procedure for screening the test and standard drugs
Test group received their respective compound 1 h prior
(400 mg/kg, p.o.) to Triton injection. The second dose of test
compound was given 20 h later (400 mg/kg, p.o.). At the end
of 24 h after Triton injection, blood was collected by retro-
orbital puncture. The animals were kept fasted throughout the
experiment period, but were provided water ad libitum. The
samples were analyzed for serum cholesterol (total) levels,
triglycerides and HDL levels as per our previous method
(Kathiravan et al., 2007) (IAECReg. No. 616/02/ac/CPCSEA).
4. Conclusions
In summary, the newly synthesized 4-substituted-2-substitut-
edmethyltriazino[6,1-b] quinazolin-10-ones and 2,4-disubsti-
tuted-6,7-dimethoxy quinazoline derivatives were evaluated
for antihyperlipidemic activity. Many synthesized compounds
exhibited promising antihyperlipidemic activity against triton
induced hyperlipidemia. Compound 5d showed the best activ-
ity in reducing % serum cholesterol level while compound 5f in
reducing % serum triglyceride level. Compound 6g is giving
best activity in case of % change in serum HDL level than
standard drug gemﬁbrozil. The results indicate that quinazo-
line nucleus shows better activity in reducing total cholesterol
as well as triglyceride level when compared with quinazoline
nucleus. Also there is signiﬁcant increase in activity in case
of 4-chloro compounds emphasizing the importance of an elec-
tronegative atom. However, quinazoline nucleus hybridized
with nicotinate has shown better results in increasing HDL
level.
Thus, we are able to improve our earlier results considerably
and compound 5d has exhibited excellent % reduction in serum
cholesterol where as 5f exhibited excellent % reduction in tri-
glyceride levels were as comparable in case of serum total cho-
lesterol levels. Among the series compound 6g has shown
promising results in lipid proﬁle. These molecules indeed have
the potential to be developed as an antihyperlipaemic molecule.
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